Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0055 AUD | +10.00% | +10.00% | +10.00% |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Sales 2022 | 3.29M 2.19M | Sales 2023 | 4.1M 2.73M | Capitalization | 25.69M 17.11M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.33M | Net income 2023 | -1M -666K | EV / Sales 2022 | 15 x |
Net cash position 2022 | 8.47M 5.65M | Net cash position 2023 | 4.08M 2.72M | EV / Sales 2023 | 5.26 x |
P/E ratio 2022 |
-22.6
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.95% |
1 day | +10.00% | ||
1 week | +10.00% | ||
Current month | +10.00% | ||
1 month | +10.00% | ||
3 months | +10.00% | ||
6 months | -8.33% | ||
Current year | +10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 20-07-12 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-10-21 | |
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Alan Yamashita
BRD | Director/Board Member | 74 | 19-02-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 0.0055 | +10.00% | 300,000 |
24-05-14 | 0.005 | -16.67% | 820,583 |
24-05-13 | 0.006 | +20.00% | 850,128 |
24-05-10 | 0.005 | 0.00% | 150,015 |
24-05-09 | 0.005 | 0.00% | 2,754,015 |
Delayed Quote Australian S.E., May 16, 2024 at 01:21 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+10.00% | 21.47M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- IVX Stock